This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Ponsioen, B. P. Articles by Bohnen, A. M. Search for Related Content PubMed PubMed Citation Articles by Ponsioen, B. P. Articles by Bohnen, A. M.

Efficacy of fluticasone on cough: a randomised controlled trial

¹ Depts of General Practice, and ² Epidemiology and Biostatistics, ErasmusMC, University Medical Center Rotterdam, Rotterdam, and ³ GlaxoSmithKline, Zeist, and ⁴ Dept of Pulmonary Diseases, University Medical Center, Nijmegen, The Netherlands

CORRESPONDENCE: B. P. Ponsioen, Dept of General Practice of ErasmusMC, University Medical Center Rotterdam, Room FF 323, PO Box 1730, 3000 DR Rotterdam, The Netherlands. Fax: 31 181413116. E-mail: b.ponsioen@erasmusmc.nl

Keywords: Adults, cough, fluticasone, primary care, smoking

Received: May 5, 2004
Accepted August 21, 2004

Cough may be the consequence of bronchial hyperresponsiveness (BHR) and inflammation. This study was designed to investigate the short-term effects of an inhaled steroid (fluticasone propionate (FP)) on cough, and to determine the effects of smoking, BHR, allergy and forced expiratory volume in one second (FEV1) on the efficacy of FP.

In a community-based primary healthcare centre, 135 previously healthy adults suffering from cough for 2 weeks were enrolled in a randomised, double-blind, placebo-controlled trial of inhaled FP 500 µg b.i.d. for 2 weeks. Participants completed daily diary cards of lower respiratory tract symptoms. The primary outcome measure was the decrease in mean total daily cough score (0–6) during the second week of treatment.

In the FP group, the cough score decreased from 3.8 at baseline to mean±SEM 1.4±0.2 during the second week. In the placebo group, this decrease was from 3.8 to 1.9±0.1 and was statistically significantly less. A favourable effect of FP was only detectable in nonsmokers, in whom the score was 0.9 points lower compared with placebo. The clinical relevance of this finding has to be established further. Allergy, FEV1 and BHR at baseline did not affect the efficacy of FP.

In conclusion, anti-inflammatory treatment with the inhaled steroid fluticasone propionate reduces cough in otherwise healthy adults who do not smoke.

This article has been cited by other articles:

				B. P. Ponsioen, A. M. Bohnen, and P. N. R. Dekhuijzen Efficacy of Fluticasone Propionate on Lung Function and Symptoms in Wheezy Infants Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 930 - 930. [Full Text] [PDF]

				P. J. F. M. Merkus and W. C. Hop Efficacy of Fluticasone Propionate on Lung Function and Symptoms in Wheezy Infants Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 930 - 931. [Full Text] [PDF]

				B. P. Ponsioen, P. N. R. Dekhuijzen, A. M. Bohnen, and N. A. Vermue From the authors Eur. Respir. J., July 1, 2005; 26(1): 181 - 182. [Full Text] [PDF]